Brind.

Clene Inc. seeks accelerated FDA approval for ALS drug CNM-Au8

1 report, 1 independent Updated Tue 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Clene Inc. submitted a New Drug Application to the U.S. Food and Drug Administration in October 2026 for its drug CNM-Au8. The filing seeks accelerated approval for amyotrophic lateral sclerosis based on neurofilament light chain biomarker data and clinical outcomes. CNM-Au8 is an investigational therapy designed to target mitochondrial function and the NAD pathway.

From dailypolitical.com

Why it matters

Some supportBrind's analysis of the reports

The submission moves the drug program into FDA review. Clene Inc. is a clinical-stage biotechnology company focused on neurodegenerative diseases. The company is still preparing the confirmatory Phase 3 RESTORE-ALS study.

From dailypolitical.com

Who's involved

  • FDARegulatory agency reviewing the drug application
  • NasdaqStock exchange where Clene Inc. trades

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • NasdaqSpeculative

    Nasdaq might see changes in market price due to the regulatory news from Clene Inc.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped